Alkermes plc (8AK) - Total Liabilities
Based on the latest financial reports, Alkermes plc (8AK) has total liabilities worth €2.51 Billion EUR (≈ $2.93 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Alkermes plc to see how much of total assets are deployed in long-term investments.
Alkermes plc - Total Liabilities Trend (2013–2025)
This chart illustrates how Alkermes plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 8AK total assets.
Alkermes plc Competitors by Total Liabilities
The table below lists competitors of Alkermes plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Terex Corporation
NYSE:TEX
|
USA | $5.42 Billion |
|
PACS Group, Inc.
NYSE:PACS
|
USA | $4.54 Billion |
|
Sailun Jinyu Group Co Ltd
SHG:601058
|
China | CN¥23.03 Billion |
|
Unicaja Banco SA
MC:UNI
|
Spain | €91.34 Billion |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
Sweden | Skr409.12 Billion |
|
Artemis Gold Inc
V:ARTG
|
Canada | CA$1.46 Billion |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
China | CN¥43.47 Billion |
|
Lamb Weston Holdings Inc
NYSE:LW
|
USA | $5.56 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Alkermes plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Alkermes plc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alkermes plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alkermes plc (2013–2025)
The table below shows the annual total liabilities of Alkermes plc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €667.70 Million ≈ $780.61 Million |
+13.06% |
| 2024-12-31 | €590.59 Million ≈ $690.46 Million |
-36.74% |
| 2023-12-31 | €933.54 Million ≈ $1.09 Billion |
+1.45% |
| 2022-12-31 | €920.23 Million ≈ $1.08 Billion |
+0.91% |
| 2021-12-31 | €911.90 Million ≈ $1.07 Billion |
+39.49% |
| 2018-12-31 | €653.72 Million ≈ $764.27 Million |
+9.98% |
| 2017-12-31 | €594.42 Million ≈ $694.94 Million |
+14.99% |
| 2016-12-31 | €516.94 Million ≈ $604.36 Million |
-4.53% |
| 2015-12-31 | €541.47 Million ≈ $633.03 Million |
+3.69% |
| 2014-12-31 | €522.22 Million ≈ $610.53 Million |
+1.92% |
| 2013-12-31 | €512.40 Million ≈ $599.05 Million |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more